|
|
|
|
|
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
注射用TB001在健康受试者的单次及多次皮下注射给药后的安全性、耐受性及药代动力学的I期临床研究
[Translation] Phase I clinical study on the safety, tolerability and pharmacokinetics of TB001 for injection after single and multiple subcutaneous injections in healthy subjects
主要目的: 评价注射用TB001在健康受试者单次及多次皮下注射给药后的安全性和耐受性。
次要目的: 评价注射用TB001在健康受试者单次及多次皮下注射给药后的药代动力学(PK)特征。 评价注射用TB001在健康受试者单次及多次皮下注射给药后的潜在药效学特征。
[Translation] Primary objective: To evaluate the safety and tolerability of TB001 for injection after single and multiple subcutaneous injections in healthy subjects.
Secondary objective: To evaluate the pharmacokinetic (PK) characteristics of TB001 for injection after single and multiple subcutaneous injections in healthy subjects. To evaluate the potential pharmacodynamic characteristics of TB001 for injection after single and multiple subcutaneous injections in healthy subjects.
100 Clinical Results associated with Qingyuan Tuwei Anchuang Technology Development Co., Ltd.
0 Patents (Medical) associated with Qingyuan Tuwei Anchuang Technology Development Co., Ltd.
100 Deals associated with Qingyuan Tuwei Anchuang Technology Development Co., Ltd.
100 Translational Medicine associated with Qingyuan Tuwei Anchuang Technology Development Co., Ltd.